TLX 123
Alternative Names: TLX-123Latest Information Update: 21 Jul 2021
At a glance
- Originator Tulex Pharmaceuticals
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 06 Jul 2021 TLX 123 is available for licensing as of 06 Jul 2021. https://www.tulexpharma.com/about/
- 06 Jul 2021 Preclinical trials in Pain in USA (PO) before July 2021 (Tulex Pharmaceuticals, July 2021)
- 06 Jul 2021 Tulex Pharmaceuitcals announces intention to seek approval from the US FDA (Tulex Pharmaceuticals website, July 2021)